London Stock Exchange welcomes 4basebio UK Societas (“4basebio”, “4bb” or the “Company”) to AIM today. The Cambridge-based Company’s Ordinary Shares were admitted to trading at 8.00am on Wednesday 17th February 2021.  

The Company’s TIDM is 4BB.LON and at the Admission price of 118p, has a market capitalisation of £14.53m. No new equity has been raised.  

On 8 December 2020, the Company was spun-out of 4basebio AG (Heidelberg), which is listed on the Frankfurt Main Market, with that company now re-focusing as an investment and holding company.  

4bb is a life sciences company focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines. Using its proprietary technology, 4bb is developing and supplying next generation therapeutic DNA, as well as non-viral nanoparticles for use in gene therapy delivery.

The Company’s focus is: 

•    developing a highly efficient and scalable manufacturing process for its proprietary synthetic hpDNATM with a view to manufacturing and selling large quantities of pharmaceutical grade DNA;
•    developing gene therapy delivery systems centred on non-viral nanoparticles; and
•    identifying a number of indications, where the combination of the company’s DNA and non-viral delivery system technology can be combined to progress potential gene therapies through pre-clinical development.

The immediate objectives of 4bb are to validate and scale its DNA synthesis process and advance its collaborations to facilitate the functional validation of its DNA based products and gene delivery solutions.

The Company is well-funded to achieve its development objectives, with approximate cash resources of £14.4million upon AIM admission.

Dr Heikki Lanckriet, Company CEO, commented: “We are delighted to be admitted to AIM today. As a Cambridge, UK based company with significant ambitions, we believe AIM is the ideal market to support our future growth.”

“We would like to thank London Stock Exchange for its warm welcome, and extend our thanks also to our staff, advisors and shareholders who have supported our ongoing development. We look forward to their continued support as we commence the next phase of our growth strategy.”